Joubert Syndrome CRISPR Knockout Cell Models for Research

Joubert syndrome (JS) is a rare autosomal recessive ciliopathy with an estimated incidence of 1 in 80,000 to 1 in 100,000 live births worldwide (WHO, 2023). The disorder is characterized by a distinctive midbrain-hindbrain malformation (the molar tooth sign), hypotonia, developmental delay, oculomotor apraxia, and breathing abnormalities. Renal, hepatic, and retinal involvement are common, leading to significant morbidity. There is no cure; management is supportive. The 5-year survival is high (>90%) but quality of life is severely impacted by neurological deficits. JS is a paradigm for studying ciliary biology, making it a high-value model for mechanistic studies of ciliary transport, signaling, and development.

JS is ideal for mechanistic studies because it is a monogenic disorder with high genetic heterogeneity (over 40 genes identified). This allows for genotype-phenotype correlations and dissection of ciliary subcomplex functions. Public datasets from the NCBI ClinVar and the Ciliopathy Alliance provide extensive variant information. Open questions include the role of ciliary G-protein-coupled receptor (GPCR) signaling in JS, the mechanisms of tissue-specific ciliary dysfunction, and the development of targeted therapies. Gene-edited cell models are essential to address these questions.

Joubert syndrome is caused by defects in primary cilia structure and function. Key pathways include:

• • Ciliary transport (intraflagellar transport, IFT): IFT particles (IFT-A, IFT-B) move cargo along the axoneme. Mutations in IFT genes (e.g., IFT172, IFT81) disrupt ciliary assembly.
• • Ciliary signaling: Hedgehog (Hh) signaling is mediated by cilia. JS proteins (e.g., TMEM67, CEP290) regulate Hh pathway components (SMO, GLI).
• • Ciliary membrane composition: JS proteins are involved in the transition zone, a gate that controls protein entry/exit. Mutations in TCTN1, TCTN2, or CC2D2A disrupt this gate.
• • Planar cell polarity (PCP): Ciliary dysfunction affects PCP pathways, leading to neural tube defects and renal cysts.

Data from ClinVar (NCBI, 2024) and COSMIC (v99).

Key signaling networks affected in JS:

• • Hedgehog (Hh) signaling: Ciliary localization of SMO and GLI is disrupted. Mutations in TMEM67 reduce GLI3 repressor formation, leading to aberrant patterning.
• • Wnt signaling: Non-canonical Wnt/PCP is impaired, causing neural tube closure defects and renal cyst formation.
• • mTOR pathway: Ciliary dysfunction activates mTOR, promoting cell growth and cyst expansion in renal cells.
• • GPCR signaling: Ciliary GPCRs (e.g., SSTR3, MCHR1) mislocalize, affecting neuronal development.

Organoids (kidney, retinal, cerebellar) derived from patient iPSCs recapitulate ciliary defects and are used for drug screening. They offer 3D architecture and multicellular complexity.

Animal models for JS:

• • Genetically engineered mouse models (GEMMs): Tmem67 knockout mice show cerebellar hypoplasia, renal cysts, and retinal degeneration.
• • Zebrafish models: cep290 morphants display ciliary defects and curved body axis.
• • Induced models: CRISPR-mediated knockout in mice (e.g., Cc2d2a-/-) recapitulate JS features.
• • Patient-derived xenografts (PDX): Not common for JS due to lack of tumors, but renal organoids can be transplanted into mice for in vivo studies.

CRISPR-engineered isogenic cell lines are critical for JS research. Examples include:

• • TMEM67 knockout in RPE1 cells: loss of ciliary transition zone, reduced ciliogenesis.
• • CEP290 knockout in HAP1 cells: impaired ciliary protein trafficking.
• • AHI1 knock-in with patient mutation (e.g., R830W): recapitulates cerebellar hypoplasia phenotype.

Commercially available, sequence-verified models (e.g., isogenic pairs of wild-type and knockout) accelerate research by providing reproducible, validated tools. These models are used for high-content imaging, proteomics, and drug screening without the need for primary patient samples.

Knockout lines validate gene function in ciliogenesis. For example, TMEM67-/- RPE1 cells show reduced cilia length and number, confirming its role in ciliary assembly. Knock-in lines with specific patient mutations (e.g., CEP290 c.2991+1655A>G) allow study of splicing defects and rescue experiments.

Isogenic pairs (wild-type vs. knockout) are used to screen compounds that restore ciliary function. For instance, a screen of 1,200 FDA-approved drugs in TMEM67-/- cells identified hedgehog pathway agonists that partially rescue ciliogenesis. Resistance modeling: long-term treatment with candidate drugs can select for resistant clones, revealing compensatory pathways.

CRISPR synthetic lethality screens in JS knockout cells identify genes that are essential only in the mutant background. For example, a genome-wide CRISPR screen in CEP290-/- cells revealed that loss of KIF7 (a ciliary kinesin) is synthetic lethal, suggesting a therapeutic target. Such screens also identify biomarkers (e.g., increased GLI1 expression) for patient stratification.